141 related articles for article (PubMed ID: 26063597)
1. The prolactin receptor as a therapeutic target in human diseases: browsing new potential indications.
Goffin V; Touraine P
Expert Opin Ther Targets; 2015; 19(9):1229-44. PubMed ID: 26063597
[TBL] [Abstract][Full Text] [Related]
2. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer.
Damiano JS; Wasserman E
Clin Cancer Res; 2013 Apr; 19(7):1644-50. PubMed ID: 23515410
[TBL] [Abstract][Full Text] [Related]
4. Discovery of the improved antagonistic prolactin variants by library screening.
Liu Y; Gong W; Breinholt J; Nørskov-Lauritsen L; Zhang J; Ma Q; Chen J; Panina S; Guo W; Li T; Zhang J; Kong M; Liu Z; Mao J; Christensen L; Hu S; Wang L
Protein Eng Des Sel; 2011 Nov; 24(11):855-60. PubMed ID: 21954059
[TBL] [Abstract][Full Text] [Related]
5. Thyrotropin-releasing hormone and oestrogen differentially regulate prolactin and prolactin receptor expression in female human skin and hair follicles in vitro.
Langan EA; Ramot Y; Hanning A; Poeggeler B; Bíró T; Gaspar E; Funk W; Griffiths CE; Paus R
Br J Dermatol; 2010 May; 162(5):1127-31. PubMed ID: 20302576
[TBL] [Abstract][Full Text] [Related]
6. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
7. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics.
Clevenger CV; Zheng J; Jablonski EM; Galbaugh TL; Fang F
J Mammary Gland Biol Neoplasia; 2008 Mar; 13(1):147-56. PubMed ID: 18246318
[TBL] [Abstract][Full Text] [Related]
8. The role of the prolactin receptor pathway in the pathogenesis of glioblastoma: what do we know so far?
Asad AS; Nicola Candia AJ; Gonzalez N; Zuccato CF; Seilicovich A; Candolfi M
Expert Opin Ther Targets; 2020 Nov; 24(11):1121-1133. PubMed ID: 32896197
[No Abstract] [Full Text] [Related]
9. Prolactin-induced prostate tumorigenesis.
Sackmann-Sala L; Goffin V
Adv Exp Med Biol; 2015; 846():221-42. PubMed ID: 25472541
[TBL] [Abstract][Full Text] [Related]
10. Development and potential clinical uses of human prolactin receptor antagonists.
Goffin V; Bernichtein S; Touraine P; Kelly PA
Endocr Rev; 2005 May; 26(3):400-22. PubMed ID: 15814850
[TBL] [Abstract][Full Text] [Related]
11. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer.
Damiano JS; Rendahl KG; Karim C; Embry MG; Ghoddusi M; Holash J; Fanidi A; Abrams TJ; Abraham JA
Mol Cancer Ther; 2013 Mar; 12(3):295-305. PubMed ID: 23270929
[TBL] [Abstract][Full Text] [Related]
12. CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.
Lim JH; Kim TY; Kim WH; Park JW
Breast Cancer Res Treat; 2011 Nov; 130(1):19-27. PubMed ID: 21128111
[TBL] [Abstract][Full Text] [Related]
13. The many faces of prolactin in breast cancer.
Chen WY
Adv Exp Med Biol; 2015; 846():61-81. PubMed ID: 25472534
[TBL] [Abstract][Full Text] [Related]
14. Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor.
Jacobson EM; Hugo ER; Tuttle TR; Papoian R; Ben-Jonathan N
Trends Endocrinol Metab; 2010 Nov; 21(11):691-8. PubMed ID: 20846877
[TBL] [Abstract][Full Text] [Related]
15. Expression of prolactin and its receptor in human breast carcinoma.
Reynolds C; Montone KT; Powell CM; Tomaszewski JE; Clevenger CV
Endocrinology; 1997 Dec; 138(12):5555-60. PubMed ID: 9389544
[TBL] [Abstract][Full Text] [Related]
16. Re-evaluation of the prolactin receptor expression in human breast cancer.
Galsgaard ED; Rasmussen BB; Folkesson CG; Rasmussen LM; Berchtold MW; Christensen L; Panina S
J Endocrinol; 2009 Apr; 201(1):115-28. PubMed ID: 19153125
[TBL] [Abstract][Full Text] [Related]
17. Prolactin in breast and prostate cancer: molecular and genetic perspectives.
Jacobson EM; Hugo ER; Borcherding DC; Ben-Jonathan N
Discov Med; 2011 Apr; 11(59):315-24. PubMed ID: 21524385
[TBL] [Abstract][Full Text] [Related]
18. Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.
Agarwal N; Machiels JP; Suárez C; Lewis N; Higgins M; Wisinski K; Awada A; Maur M; Stein M; Hwang A; Mosher R; Wasserman E; Wu G; Zhang H; Zieba R; Elmeliegy M
Oncologist; 2016 May; 21(5):535-6. PubMed ID: 27091421
[TBL] [Abstract][Full Text] [Related]
19. Prolactin stimulates cell migration and invasion by human trophoblast in vitro.
Stefanoska I; Jovanović Krivokuća M; Vasilijić S; Ćujić D; Vićovac L
Placenta; 2013 Sep; 34(9):775-83. PubMed ID: 23849393
[TBL] [Abstract][Full Text] [Related]
20. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells.
Gutzman JH; Miller KK; Schuler LA
J Steroid Biochem Mol Biol; 2004 Jan; 88(1):69-77. PubMed ID: 15026085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
